[Federal Register Volume 66, Number 141 (Monday, July 23, 2001)]
[Notices]
[Page 38322]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 01-18218]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances, Notice of Application

    Pursuant to Section 1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on December 12, 2000, Johnson 
Matthey, Inc., Custom Pharmaceuticals Department, 2003 Nolte Drive, 
West Deptford, New Jersey 08066, made application by renewal to the 
Drug Enforcement Administration (DEA) for registration as a bulk 
manufacturer of the basic classes of controlled substances listed 
below:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Tetrahydrocannabinols (7370)................  I
Difenoxin (9168)............................  I
Propriam (9649).............................  I
Amphetamine (1100)..........................  II
Methylphenidate (1724)......................  II
Anileridine (9020)..........................  II
Codeine (9050)..............................  II
Oxycodone (9143)............................  II
Hydromorphone (9150)........................  II
Hydrocodone (9193)..........................  II
Meperidine (9230)...........................  II
Morphine (9300).............................  II
Thebaine (9333).............................  II
Alfentanil (9737)...........................  II
Sufentanil (9740)...........................  II
Fentanyl (9801).............................  II
------------------------------------------------------------------------

    The firm plans to manufacture the listed controlled substances in 
bulk to supply final dosage from manufacturers.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such substances may file comment or objections 
to the issuance of the proposed registration.
    Any such comments or objections may be addressed, in quintuplicate, 
to the Deputy Assistant Administrator, Office of Diversion Control, 
Drug Enforcement Administration, United States Department of Justice, 
Washington, DC 20537, Attention: DEA Federal Register Representative 
(CCR), and must be filed no later than (60 days from publication).

    Dated: July 13, 2001.
Laura M. Nagel,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 01-18218 Filed 7-20-01; 8:45 am]
BILLING CODE 4410-09-M